Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
View original at finance.yahoo.comUpdated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Updated EMBER-3 data demonstrate continued clinically meaningful benefit for patients receiving monotherapy and those receiving the combination with abemaciclib, reinforcing Inluriyo's role in the treatment setting
80% confidenceEli Lilly is encouraged by the potential of an all-oral combination with imlunestrant and abemaciclib
80% confidenceThe median progression-free survival of 11 months is among the longest seen in ER+, HER2– metastatic breast cancer population
80% confidenceEli Lilly medicines help tens of millions of people globally
80% confidenceBreast cancer is the 2nd most diagnosed cancer worldwide after lung cancer
80% confidenceWith an additional year of follow-up, EMBER-3 results strengthen the case for imlunestrant-based regimens in ER+, HER2– metastatic breast cancer
80% confidence